Haemonetics (NYSE:HAE) Price Target Cut to $95.00 by Analysts at Barrington Research

Haemonetics (NYSE:HAE) had its price target reduced by Barrington Research from $108.00 to $95.00 in a report released on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price objective indicates a potential upside of 50.91% from the stock’s current price.

HAE has been the subject of several other reports. Needham & Company LLC reissued a “buy” rating and set a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. assumed coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Finally, Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Haemonetics Stock Down 11.6 %

Shares of NYSE:HAE opened at $62.95 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a 52-week low of $61.43 and a 52-week high of $97.97. The business’s 50 day simple moving average is $77.44 and its two-hundred day simple moving average is $78.73. The firm has a market cap of $3.16 billion, a P/E ratio of 26.12, a PEG ratio of 1.07 and a beta of 0.39.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. As a group, research analysts forecast that Haemonetics will post 4.59 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds have recently made changes to their positions in HAE. Global Alpha Capital Management Ltd. increased its holdings in Haemonetics by 70.6% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 17,101 shares of the medical instruments supplier’s stock worth $1,335,000 after acquiring an additional 7,076 shares during the last quarter. AMG National Trust Bank bought a new position in Haemonetics during the fourth quarter worth about $746,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Haemonetics in the fourth quarter worth about $284,000. Raymond James Financial Inc. bought a new stake in shares of Haemonetics in the fourth quarter valued at approximately $19,002,000. Finally, Arizona State Retirement System lifted its stake in shares of Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock valued at $1,160,000 after buying an additional 181 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.